Caricamento...
Emerging therapies in advanced hepatocellular carcinoma
BACKGROUND: Prognosis is very poor for advanced HCC patients partially due to lack of effective systemic treatment. Sorafenib was the only approved agent for advanced HCC since 2007 until recent breakthroughs. In this article, we will review the newer approved and promising agents in the treatment o...
Salvato in:
| Pubblicato in: | Exp Hematol Oncol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6076403/ https://ncbi.nlm.nih.gov/pubmed/30087805 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0109-6 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|